In Focus: recent therapies for breast cancer
In our latest In Focus we are shining a light on treatment options for subtypes of breast cancer through an infographic, panel discussion and news articles. Check out the infographic to gain a visual snapshot of HR+/HER2- breast cancer and make sure to read our panel discussion in which a group of oncologists provide their clinical case studies.
FEATURES
Panel discussion: how I treat metastatic HER2-positive breast cancer
Gain an understanding of how oncologists are treating metastatic HER2-positive breast cancer in Oncology Central’s latest panel discussion, featuring experts from international institutions.
Infographic: recent therapies for HR+/HER2- breast cancer
This infographic explores the current treatment options for HR+/HER2- breast cancer cancer, their limitations and predictions for the future of the treatment landscape.
NICE recommends abemaciclib with fulvestrant for advanced HR+/HER2- breast cancer
This news story describes the recent draft guidance from NICE recommending abemaciclib (Verzenios®) with fulvestrant (Faslodex®) for locally advanced or metastatic HR-positive, HER2-negative breast cancer previously treated with endocrine therapy.
The OlympiA Phase III trial recently presented results of their interim analysis, reporting that olaparib offered a 3-year invasive disease-free survival of 85.9% in high-risk, early stage HER2-negative breast cancer patients harboring BRCA 1/2 mutations.